Day: March 27, 2025

CORRECTION: Harju Elekter Group’s audited Annual Report 2024

Written by Customer Service on March 27, 2025. Posted in Public Companies.

In the published notice, the year has been corrected (correct 2024). AS Harju Elekter Group presents its consolidated audited Annual Report for 2024 prepared by the Management Board and approved by the Supervisory Board. Compared to the unaudited interim report published on 20 February 2025, there are no differences in the audited financial results. The consolidated audited revenue for the year 2024 was 174.7 million euros, the operating profit was 6.4 million euros and net profit 3.2 million euros. The original audited Annual Report 2024 document is submitted in machine-readable .xhtml format to the Nasdaq Tallinn Stock Exchange and digitally signed (link: https://nasdaqbaltic.com/statistics/en/instrument/EE3100004250/reports). Tiit AtsoChairman of the Management Board+372 674 7400AttachmentsHEG Annual Report 2024 ...

Invitation to the Annual General Meeting of shareholders of AS Harju Elekter Group, its agenda, and proposals

Written by Customer Service on March 27, 2025. Posted in Public Companies.

The Management Board of AS Harju Elekter Group (registry code 10029524, registry address Paldiski mnt 31/2, Keila) convenes the Annual General Meeting of shareholders. The General Meeting will take place on 24 April 2025 at 10:00 a.m. at venue of Nordic Hotel Forum (Capella hall), address Viru väljak 3, Tallinn. Registration of meeting participants will start on 24 April 2025 at 09:00 a.m. The list of shareholders entitled to vote at the meeting is fixed seven days before the General Meeting, i.e. as of the end of the business day of the Nasdaq CSD Estonian settlement system on 17 April 2025. Shareholders can vote on the items on the agenda before the General Meeting by e-mail or post. A more detailed overview of how it is possible to vote before the General Meeting, is provided in the section “Organisational issues” of this notice...

Harju Elekter Group’s audited Annual Report 2024

Written by Customer Service on March 27, 2025. Posted in Public Companies.

AS Harju Elekter Group presents its consolidated audited Annual Report for 2024 prepared by the Management Board and approved by the Supervisory Board. Compared to the unaudited interim report published on 20 February 2025, there are no differences in the audited financial results. The consolidated audited revenue for the year 2024 was 174.7 million euros, the operating profit was 6.4 million euros and net profit 3.2 million euros. The original audited Annual Report 2023 document is submitted in machine-readable .xhtml format to the Nasdaq Tallinn Stock Exchange and digitally signed (link: https://nasdaqbaltic.com/statistics/en/instrument/EE3100004250/reports). Tiit AtsoChairman of the Management Board+372 674 7400AttachmentsHEG Annual Report 2024Harju Elekter Group aastaaruanne 2024 EST ESEF

Discovery Reports Fourth Quarter & Full-Year 2024 Financial Results

Written by Customer Service on March 27, 2025. Posted in Earnings Releases And Operating Results.

TORONTO, March 26, 2025 (GLOBE NEWSWIRE) — Discovery Silver Corp. (TSX: DSV, OTCQX: DSVSF) (“Discovery” or the “Company”) today announced financial results for the three months (“Q4 2024”) and full-year (“FY 2024”) ended December 31, 2024. All figures are stated in Canadian dollars unless otherwise noted. Tony Makuch, Discovery’s CEO, commented: “2024 was a transformational year for Discovery as we work towards becoming a highly profitable North American precious metals producer. Through the efforts of our team, today we stand poised to become a diversified gold and silver company, with a portfolio that combines growing gold production in the Timmins Camp, with tremendous upside, with our Cordero project (“Cordero”) in Mexico, one of the industry’s leading silver development projects. “In February 2024, we issued the Cordero feasibility...

Junshi Biosciences Announces Toripalimab’s Approval in Singapore

Written by Customer Service on March 27, 2025. Posted in Public Companies.

SHANGHAI, March 26, 2025 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the New Drug Application (the “NDA”) for toripalimab (Singapore trade name: LOQTORZI®) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma (“NPC”) has been approved by the Singapore Health Sciences Authority (the HSA). Toripalimab has become the first and only approved immuno-oncology treatment for NPC in Singapore. NPC is a malignant tumor that occurs in the epithelium mucosae of the nasopharynx and is one of the most...

Yukon Metals Announces C$5M Private Placement

Written by Customer Service on March 27, 2025. Posted in Public Companies.

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES/ VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) — Yukon Metals Corp. (CSE: YMC, FSE: E770, OTC: YMMCF) (“Yukon Metals” or the “Company”) is pleased to announce that it has entered into an agreement with Cormark Securities Inc. and Canaccord Genuity Corp. (the “Co-Agents”) to act as co-agents in connection with a “best efforts” private placement for aggregate gross proceeds of up to approximately C$5 million (the “Offering”). The Offering will consist of the issuance and sale of up to 9,090,909 units of the Company (the “Units”) at a price of C$0.55 per Unit (the “Issue Price”). Each Unit will consist of one common share of the Company (each, a “Unit Share”) and...

Banco Itaú Chile Files Material Event Notice announcing Dividend Distribution Proposal

Written by Customer Service on March 27, 2025. Posted in Dividend Reports And Estimates.

SANTIAGO, Chile, March 26, 2025 (GLOBE NEWSWIRE) — BANCO ITAÚ CHILE (SSE: ITAUCL) (the “Bank”) today announced that its Board of Directors has agreed, in its ordinary meeting held on this same date, to propose to the Ordinary Shareholders’ Meeting, to be held on April 24, 2025, the distribution of 30% of the profits for the 2024 fiscal year, corresponding to the amount of $112,988,077,742 as a dividend to shareholders, among the total of the Bank’s 216,340,749 validly issued shares in circulation. Therefore, if approved as indicated, a dividend of $522.2690513195920 per share would be distributed. Additionally, it will be proposed to the Shareholders’ Meeting that the remaining 70% of the profits be retained. The dividends that are approved will be available to shareholders starting on May 7, 2025. In this regard, shareholders...

Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva

Written by Customer Service on March 27, 2025. Posted in Public Companies.

PALO ALTO, Calif., March 26, 2025 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, in neurodegenerative and cardiometabolic disease, reiterates that it has appealed a lower court decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and will continue to vigorously pursue its infringement action on appeal against Aveva Drug Delivery Systems, Inc. (“Aveva”). In May 2022, Scilex received notice that a pharmaceutical maker, Aveva and its former related entities, Apotex Corp. and Apotex Inc. (collectively, the “Apotex Parties”),...

Ryoncil® is Now Available for Purchase in the United States

Written by Customer Service on March 27, 2025. Posted in Public Companies.

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Ryoncil® (remestemcel-L) the first mesenchymal stromal cell (MSC) therapy approved by U.S. Food and Drug Administration (FDA) for any indication, is now available for purchase in the United States. Ryoncil® is approved for treatment of pediatric patients 2 months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease (SR-aGvHD), a condition with high mortality rates. The recommended dosage of Ryoncil® for treatment of pediatric SR-aGvHD is 2×106 MSC/kg body weight per intravenous infusion given twice per week for 4 consecutive weeks. To assist patients and institutions with insurance coverage, financial...

LeddarTech Reports Annual Shareholder Meeting Results

Written by Customer Service on March 27, 2025. Posted in Public Companies.

QUEBEC CITY, Canada, March 26, 2025 (GLOBE NEWSWIRE) — LeddarTech® Holdings Inc. (“LeddarTech” or the “Corporation”) (Nasdaq: LDTC), an automotive software company that provides patented disruptive AI-powered low-level sensor fusion and perception software technology, LeddarVision™, announces the voting results of its annual general and special meeting of shareholders held on March 26, 2025 (the “Meeting”). Shareholders voted on various proposals and elected directors to the board. Key Highlights of the Meeting 1. Election of Directors: The full slate of six directors was elected to serve until the next annual meeting of shareholders or until a successor is elected or appointed.Nominee Votes For % of Voted Votes Against % of VotedFrantz Saintellemy 22,429,293 99.69% 68,631 0.31%Charles Boulanger 22,392,108 99.53% 105,816 0.47%Derek...

Day: March 27, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals